Xeris Biopharma Holdings Past Earnings Performance
Past criteria checks 0/6
Xeris Biopharma Holdings has been growing earnings at an average annual rate of 2.3%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 62.8% per year.
Key information
2.3%
Earnings growth rate
43.8%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 62.8% |
Return on equity | n/a |
Net Margin | -38.0% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Xeris Biopharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 164 | -62 | 146 | 22 |
30 Sep 23 | 153 | -62 | 134 | 21 |
30 Jun 23 | 134 | -71 | 131 | 22 |
31 Mar 23 | 121 | -78 | 127 | 20 |
31 Dec 22 | 110 | -95 | 136 | 21 |
30 Sep 22 | 99 | -133 | 158 | 26 |
30 Jun 22 | 80 | -137 | 150 | 26 |
31 Mar 22 | 63 | -138 | 143 | 27 |
31 Dec 21 | 50 | -123 | 116 | 25 |
30 Sep 21 | 35 | -94 | 90 | 18 |
30 Jun 21 | 34 | -84 | 79 | 16 |
31 Mar 21 | 27 | -80 | 71 | 16 |
31 Dec 20 | 20 | -91 | 74 | 19 |
30 Sep 20 | 15 | -102 | 76 | 28 |
30 Jun 20 | 6 | -119 | 75 | 40 |
31 Mar 20 | 4 | -129 | 72 | 54 |
31 Dec 19 | 3 | -126 | 63 | 60 |
30 Sep 19 | 2 | -113 | 51 | 60 |
30 Jun 19 | 2 | -95 | 41 | 56 |
31 Mar 19 | 2 | -73 | 30 | 45 |
31 Dec 18 | 2 | -60 | 21 | 41 |
30 Sep 18 | 2 | -49 | 15 | 35 |
30 Jun 18 | 2 | -42 | 13 | 30 |
31 Mar 18 | 1 | -34 | 10 | 25 |
31 Dec 17 | 2 | -27 | 8 | 20 |
31 Dec 16 | 1 | -13 | 4 | 10 |
Quality Earnings: 2B30 is currently unprofitable.
Growing Profit Margin: 2B30 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2B30 is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.
Accelerating Growth: Unable to compare 2B30's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2B30 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 2B30's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.